Immune · Reference
How Long Does Thymosin Alpha-1 Take to Work? What the Trials Measured, and When
This page goes through each trial's length and what it measured, explains why an immune modulator has no "feel it working" moment, and covers your directions and what to track.
Treatments mentioned
No trial has measured how long thymosin alpha-1 takes to work for immune support in healthy adults, and it does not produce a sensation, so noticing nothing is normal. The human trials that exist have clear timing: sepsis trials judged mortality at 28 days, a hepatitis B trial gave 26- or 52-week courses and measured response at 18 months, and a hepatitis C trial ran 48 weeks. In the hepatitis B trial, responses accumulated after the course had finished rather than during it, and the largest trial of all, 1,106 adults with sepsis, found no clear mortality benefit. Compounded thymosin alpha-1 is not FDA approved.
This page goes through each trial's length and what it measured, explains why an immune modulator has no "feel it working" moment, and covers your directions and what to track.
How Long Does Thymosin Alpha-1 Take to Work? What the Trials Measured, and When
The short answer
| Trial | Who | How long | What was measured, and when |
|---|---|---|---|
| Hepatology, 1998 | 98 people with chronic hepatitis B | A 26-week course, a 52-week course, or no treatment | Complete virological response at 18 months: 40.6%, 26.5% and 9.4%; responses accumulated after the course finished |
| Journal of Viral Hepatitis, 2012 | 552 people with hepatitis C who had not responded to interferon-based treatment | 48 weeks, added to that treatment | Sustained viral response: 12.7% against 10.5%, not different |
| ETASS, Critical Care, 2013 | 361 people with severe sepsis | Hospital treatment, judged at 28 days | 28-day mortality 26.0% against 35.0%, marginal significance |
| TESTS, BMJ, 2025 | 1,106 adults with sepsis, double-blind, placebo-controlled | Hospital treatment, judged at 28 days | 28-day mortality 23.4% against 24.1%; no clear benefit |
| Journal of Clinical Oncology, 2010 | 488 people with metastatic melanoma, with chemotherapy | Through treatment and survival follow-up | Median survival 9.4 against 6.6 months, not significant |
| Clinical Infectious Diseases, 2020 | 76 people with severe COVID-19, retrospective | Hospital stay | Lower mortality and higher CD4 and CD8 counts in treated patients; not confirmed by later randomised work |
| Cochrane review, 2026 | 10 randomised hepatitis B trials, 1,349 people | Across trials | May reduce mortality and serious adverse events; very low certainty |
Every trial enrolled people with a serious infection or cancer. The timing in each was set by the disease being measured, not by the peptide.
How Long Does Thymosin Alpha-1 Take to Work? What the Trials Measured, and When
Why there is no "feel it working" moment
It is a modulator, not a stimulant
Thymosin alpha-1 is a 28-amino-acid peptide first isolated from calf thymus in 1977. In cell and animal work it acts on Toll-like receptors on dendritic cells, promotes T-cell maturation and increases natural killer cell activity, and in some settings pushes the response toward regulatory T cells and tolerance. A 2010 review called it "the regulator of regulators". None of that is something a person feels. There is no rush, no change in energy that the trials recorded, and no physical cue that it has started.
The measurable effects are laboratory values
The closest thing to a human time course for the mechanism is a laboratory one: the 2020 COVID-19 report measured a rise in circulating CD4 and CD8 T cells in treated patients during their hospital stay. A change in a cell count is a laboratory endpoint. Whether it means anything a person would notice depends on why they were treated, and often it would not be perceptible.
The disease sets the clock
Sepsis is measured at 28 days because that is how sepsis outcomes are judged. Hepatitis B was measured at 18 months because viral clearance is slow. These timings describe the diseases. They say nothing about how long it takes for someone without those diseases to notice anything, and there is no trial of that.
Some effects showed up after treatment stopped
The 1998 hepatitis B trial is the most interesting timing result in the literature. Responses kept accumulating after the 26- or 52-week course had finished, and the shorter course had the higher response rate at 18 months. That is a reminder that immune effects can lag treatment, and that the moment you stop a vial is not necessarily the moment to judge it. It is one small trial in a single disease, in an era before modern antivirals.
The biggest trial is the one to remember
TESTS, published in the BMJ in 2025, is the largest and best-designed trial of thymosin alpha-1 in any indication, and it was negative on its main endpoint. The earlier, smaller sepsis result did not hold up. This is the single most important fact for reading any claim about thymosin alpha-1, including any claim about how quickly it works.
How Long Does Thymosin Alpha-1 Take to Work? What the Trials Measured, and When
What your directions look like
| What the label shows | Value |
|---|---|
| Product | Thymosin Alpha-1, 5 mL multi-dose vial at 2 mg/mL (10 mg per vial) |
| Typical directions | Inject 0.25 mL (25 units) subcutaneously once daily Monday through Friday |
| Thymosin alpha-1 per dose | 0.5 mg (2 mg/mL x 0.25 mL) |
| Doses per vial | 20, about four weeks |
| Price | $249/mo, all-in |
| Other formats | A 3 mL pre-filled Pen cartridge containing 15 mg, dosed by dial; FORTIFY, $289/mo, with BPC-157, KPV and LL-37 |
The trials did not use this schedule. The branded product's schedule, 1.6 mg twice weekly, is not the compounded direction, and no dose or duration has been established for any use outside the trials. Refills run every 28 days, one vial per fill, and vials ship ready to use, refrigerated with ice packs, with sterile syringes and alcohol prep pads. Your physician sets your directions after reviewing your intake, and they are printed on the vial. The conversion chart is in thymosin alpha 1 dosage.
How Long Does Thymosin Alpha-1 Take to Work? What the Trials Measured, and When
What to track, and when to message your care team
Because thymosin alpha-1 has no felt effect, a record of what actually happens is more useful than waiting for a sensation.
| Keep a note of | Why |
|---|---|
| Why you started, in one sentence, before the first dose | So the question you are answering does not drift |
| Infections: when, how long, how severe | The outcome most people care about, and one memory distorts |
| Sleep, stress and travel | Ordinary drivers of how often people get ill |
| Any autoimmune symptoms | It is described as acting on immune regulation; raise autoimmune disease or immunosuppressive treatment with your care team |
| Injection-site redness, soreness or bruising | The commonest reported effect |
Frequent illness or fatigue without an immune finding usually has an ordinary cause first, and peptides for immune support covers what is known about each option. Message your care team about any reaction that does not settle or any new symptom. A severe or spreading reaction, facial or throat swelling or difficulty breathing is an emergency: call 911. More is in thymosin alpha-1 side effects.
Do not raise your own dose and do not start another product in the same weeks; with nothing to feel, your notes are the only signal there is.
How Long Does Thymosin Alpha-1 Take to Work? What the Trials Measured, and When
What the evidence shows, honestly
Thymosin alpha-1 has more human trial evidence than almost any other compounded peptide, and it is consistently reported as well tolerated, with adverse-event rates similar to placebo in the randomised trials. The results are mixed: consistent signals at very low certainty in hepatitis B, a negative hepatitis C trial, a negative large sepsis trial, and a melanoma signal short of significance. There are no randomised trials for immune support in otherwise healthy adults.
On regulation: thymosin alpha-1 was placed in Category 2 of the FDA's interim 503A list in 2023 and removed effective 27 September 2024 after the nomination was withdrawn. On 4 December 2024 the Pharmacy Compounding Advisory Committee voted 4 to 17 against adding it to the 503A Bulks List. The FDA has not issued a final determination, and on its list updated 14 May 2026 it appears in no 503A category. It is not approved for any use in the United States, and compounded medications are not FDA approved. It is not named on the 2026 WADA Prohibited List, but the S0 class covers substances without regulatory approval for human therapeutic use, so tested athletes should confirm first. The benefit-by-benefit evidence is in thymosin alpha 1 benefits and the full reference is what is thymosin alpha-1.
How Long Does Thymosin Alpha-1 Take to Work? What the Trials Measured, and When
Where to get thymosin alpha-1 prescribed
Thymosin alpha-1 cannot be bought legitimately without a prescription. Sites selling it "for research use only" are not accountable for identity, purity, sterility or concentration, which matters for a peptide where one of the FDA's stated concerns was immunogenicity from impure material. The prescription route:
- Complete a free online intake covering your history, medications and what you want help with.
- A physician licensed in your state reviews it, usually within 24 hours.
- If it is appropriate, a PCAB-accredited, FDA-registered US 503A compounding pharmacy prepares it to that prescription. Lot test results are published at /quality/lab-results.
- It ships refrigerated with your directions printed on the vial.
- Your physician stays reachable for questions and side effects.
Pepti prescribes thymosin alpha-1 in every state except Oklahoma, plus DC, cash-pay, with no insurance billing and no membership fee. Step by step: how to get thymosin alpha-1 prescribed online. The name is often confused with a repair peptide; thymosin alpha-1 vs TB-500 sets them apart.
References
What this is based on.
References
- Dominari A, Hathaway Iii D, Pandav K et al.. Thymosin alpha 1: A comprehensive review of the literature · World J Virol (2020) · PMID 33362999
- Pierluigi B, D'Angelo C, Fallarino F et al.. Thymosin alpha1: the regulator of regulators? · Ann N Y Acad Sci (2010) · PMID 20536444
- Wu J et al.. The efficacy and safety of thymosin α1 for sepsis (TESTS): multicentre, double blinded, randomised, placebo controlled, phase 3 trial · BMJ (2025) · PMID 39814420
- Wu J et al.. The efficacy of thymosin alpha 1 for severe sepsis (ETASS): a multicenter, single-blind, randomized and controlled trial · Crit Care (2013) · PMID 23327199
- Naing C et al.. Thymosin-ɑ1 for people with chronic hepatitis B · Cochrane Database Syst Rev (2026) · PMID 42713852
- Chien RN et al.. Efficacy of thymosin alpha1 in patients with chronic hepatitis B: a randomized, controlled trial · Hepatology (1998) · PMID 9581695
- Yang YF et al.. Comparison of the efficacy of thymosin alpha-1 and interferon alpha in the treatment of chronic hepatitis B: a meta-analysis · Antiviral Res (2008) · PMID 18078676
- Ciancio A et al.. Thymosin alpha-1 with peginterferon alfa-2a/ribavirin for chronic hepatitis C not responsive to IFN/ribavirin: an adjuvant role? · J Viral Hepat (2012) · PMID 22233415
- Maio M et al.. Large randomized study of thymosin alpha 1, interferon alfa, or both in combination with dacarbazine in patients with metastatic melanoma · J Clin Oncol (2010) · PMID 20194853
- Liu Y et al.. Thymosin Alpha 1 Reduces the Mortality of Severe Coronavirus Disease 2019 by Restoration of Lymphocytopenia and Reversion of Exhausted T Cells · Clin Infect Dis (2020) · PMID 32442287
- Camerini R, Garaci E. Historical review of thymosin α 1 in infectious diseases · Expert Opin Biol Ther (2015) · PMID 26098768
- Gravenstein S, Duthie EH, Miller BA, Roecker E, Drinka P, Prathipati K, Ershler WB. Augmentation of influenza antibody response in elderly men by thymosin alpha one. A double-blind placebo-controlled clinical study · J Am Geriatr Soc (1989) · PMID 2642497
Citations are provided for educational purposes. They do not constitute medical advice. Always discuss any peptide protocol with your prescribing physician.
Common questions
How Long Does Thymosin Alpha-1 Take to Work? What the Trials Measured, and When, answered.
No trial has measured that for immune support in healthy adults, and it produces no sensation. The disease trials had their own clocks: 28 days in sepsis, 18 months in hepatitis B, 48 weeks in hepatitis C.
Most likely not. It is described as an immune modulator, and the trials measured laboratory values and disease outcomes rather than anything a person feels. Noticing nothing is normal.
The hepatitis B trial used 26- or 52-week courses with response judged at 18 months, the hepatitis C trial ran 48 weeks, and the sepsis trials judged mortality at 28 days.
In the 1998 hepatitis B trial, responses accumulated after the course finished rather than during it. That is one small trial in one disease, and it has not been studied in healthy adults.
A 2020 retrospective report in severe COVID-19 measured higher CD4 and CD8 counts in treated patients during their hospital stay. There is no time course for this in healthy people.
No. Take the dose printed on your vial, on the schedule printed on your vial. Tell your care team what you are and are not noticing.
About four weeks: 20 doses of 0.25 mL, once daily Monday through Friday.
Yes. Thymalfasin is the generic name. Compounded thymosin alpha-1 is the same sequence but is not the branded product and carries none of its foreign approvals.
No. It is not approved for any use in the United States, and compounded medications are not FDA approved.
No. Bloodwork is not required for any Pepti treatment. If your physician wants labs for your care, they'll ask through your account. The free assessment goes to a physician licensed in your state. A consultation does not guarantee a prescription.
Next step
See what a physician recommends for you.
A licensed physician in your state reviews your intake and decides what is appropriate. A consultation does not guarantee a prescription.